NASDAQ:ACRS

Aclaris Therapeutics - ACRS Stock Forecast, Price & News

$15.68

+0.33 (+2.15%)

(As of 10/4/2022 01:32 PM ET)

Add

Compare

Today's Range: $15.65
▼
$16.02
50-Day Range: $13.07
▼
$18.22
52-Week Range: $9.26
▼
$18.75

Volume: 5,352 shs
Average Volume: 378,021 shs
Market Capitalization: $1.05 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $38.00

Aclaris Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 140.2% Upside
$38.00 Price Target
Short Interest: Bearish
6.38% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.87
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.47) to ($1.55) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

890th out of 1,087 stocks

Pharmaceutical Preparations Industry

440th out of 546 stocks

3.5

Analyst's Opinion

Consensus Rating
Aclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $38.00, Aclaris Therapeutics has a forecasted upside of 140.2% from its current price of $15.82.
Amount of Analyst Coverage
Aclaris Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.38% of the float of Aclaris Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Aclaris Therapeutics has a short interest ratio ("days to cover") of 9.5.
Change versus previous month
Short interest in Aclaris Therapeutics has recently increased by 5.10%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aclaris Therapeutics does not currently pay a dividend.
Dividend Growth
Aclaris Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACRS.

3.3

News and Social Media Coverage

News Sentiment
Aclaris Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Aclaris Therapeutics this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.70% of the stock of Aclaris Therapeutics is held by insiders.
Percentage Held by Institutions
95.08% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aclaris Therapeutics are expected to decrease in the coming year, from ($1.47) to ($1.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aclaris Therapeutics is -11.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aclaris Therapeutics is -11.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aclaris Therapeutics has a P/B Ratio of 4.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aclaris Therapeutics (NASDAQ:ACRS) Stock

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock News Headlines

September 27, 2022 | finance.yahoo.com

Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

August 30, 2022 | finance.yahoo.com

Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 25, 2022 | finance.yahoo.com

Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata

August 9, 2022 | msn.com

Looking Into Aclaris Therapeutics Return On Capital Employed

August 5, 2022 | finance.yahoo.com

Health Check: How Prudently Does Aclaris Therapeutics (NASDAQ:ACRS) Use Debt?

August 3, 2022 | finance.yahoo.com

Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

July 15, 2022 | finance.yahoo.com

Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy

July 1, 2022 | finance.yahoo.com

Lab Notes: Verrica continues push for skin disorder drug, raising $25M; Windtree weighing options

June 27, 2022 | seekingalpha.com

Aclaris Therapeutics appoints Gail Cawkwell as Chief Medical Officer

June 20, 2022 | nasdaq.com

Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?

May 27, 2022 | finance.yahoo.com

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 179%: Here's is How to Trade

May 10, 2022 | ca.investing.com

Aclaris Therapeutics Tops Q1 EPS by 9c

May 10, 2022 | finance.yahoo.com

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

May 10, 2022 | finance.yahoo.com

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

May 9, 2022 | seekingalpha.com

Aclaris Therapeutics Q1 2022 Earnings Preview

May 5, 2022 | finance.yahoo.com

Lannett (LCI) Reports Q3 Loss, Lags Revenue Estimates

May 3, 2022 | finance.yahoo.com

Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium

April 13, 2022 | finance.yahoo.com

FEC Resources Reports on SC 72 Force Majeure Declaration

February 24, 2022 | finance.yahoo.com

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue Estimates

February 21, 2022 | finance.yahoo.com

Those who invested in Aclaris Therapeutics (NASDAQ:ACRS) three years ago are up 97%

February 17, 2022 | finance.yahoo.com

Earnings Preview: Aclaris Therapeutics (ACRS) Q4 Earnings Expected to Decline

February 2, 2022 | finance.yahoo.com

Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference

January 13, 2022 | seekingalpha.com

Bed Bath & Beyond, Orphazyme lead postmarket gainers; Gogo, Biogen among losers

January 12, 2022 | msn.com

The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award

January 11, 2022 | seekingalpha.com

Aclaris falls on the exit of medical chief

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Company Calendar

Last Earnings: 8/03/2022
Today: 10/04/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACRS
CUSIP: N/A
CIK: 1557746
Web: www.aclaristx.com
Phone: (484) 324-7933
Fax: 484-320-2344
Employees: 72
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $38.00
High Stock Price Forecast: $50.00
Low Stock Price Forecast: $26.00
Forecasted Upside/Downside: +142.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-90,860,000.00
Net Margins: -1,355.98%
Pretax Margin: -1,355.98%
Return on Equity: -40.14%
Return on Assets: -32.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.99
Quick Ratio: 15.99

Sales & Book Value

Annual Sales: $6.76 million
Price / Sales: 154.64
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.22 per share
Price / Book: 4.87

Miscellaneous

Outstanding Shares: 66,670,000
Free Float: 62,205,000
Market Cap: $1.05 billion
Optionable: Optionable
Beta: 0.58

Key Executives

Dr. Neal S. Walker D.O. (Age 52)
Co-Founder, CEO & Director
Comp: $965.59k

Mr. Frank Ruffo (Age 56)
Co-Founder, CFO , Sec. & Treasurer
Comp: $590.85k

Dr. Joseph Monahan
Chief Scientific Officer

Dr. Douglas J. Manion Frcp(C) (Age 61)
M.D., Pres & COO

Mr. Matthew Rothman J.D.
VP of Legal & Compliance

Dr. Jon Jacobsen Ph.D.
Sr. VP of Chemistry

Dr. Paul S. Changelian Ph.D.
Sr. VP of Biology

Mr. James Loerop (Age 57)
Chief Bus. Officer

Dr. Ian Anderson Ph.D.
Exec. VP of Translational R&D

Dr. Gail Cawkwell M.D. (Age 60)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACRS Stock - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings or view top-rated stocks.
What is Aclaris Therapeutics' stock price forecast for 2022?: 4 Wall Street research analysts have issued 12 month target prices for Aclaris Therapeutics' shares. Their ACRS share price forecasts range from $26.00 to $50.00. On average, they predict the company's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 147.6% from the stock's current price.
View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts.
How have ACRS shares performed in 2022?: Aclaris Therapeutics' stock was trading at $14.54 on January 1st, 2022. Since then, ACRS shares have increased by 5.6% and is now trading at $15.35.
View the best growth stocks for 2022 here.
When is Aclaris Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our ACRS earnings forecast.
How were Aclaris Therapeutics' earnings last quarter?: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) posted its earnings results on Wednesday, August, 3rd. The biotechnology company reported ($0.31) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.05. The biotechnology company earned $1.53 million during the quarter, compared to analyst estimates of $1.59 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 40.14% and a negative net margin of 1,355.98%.

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?: 1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Aclaris Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX).
What is Aclaris Therapeutics' stock symbol?: Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."
How do I buy shares of Aclaris Therapeutics?: Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aclaris Therapeutics' stock price today?: One share of ACRS stock can currently be purchased for approximately $15.35.
How much money does Aclaris Therapeutics make?: Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $1.02 billion and generates $6.76 million in revenue each year. The biotechnology company earns $-90,860,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.
How can I contact Aclaris Therapeutics?: Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.

This page (NASDAQ:ACRS) was last updated on 10/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aclaris Therapeutics - ACRS Stock Forecast, Price & News

Aclaris Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month